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We recently showed that both replicating and resting cells cultivated with ganciclovir (GCV) were killed when challenged with vesicular
stomatitis virus G glycoprotein pseudotyped HIV-1-based virus-like particles (VLPs) carrying the Nef7 (i.e., an HIV-1 Nef mutant incorporating in
virions at high levels)/herpes simplex virus-1 thymidine kinase (HSV-TK) fusion product. On this basis, a novel anti-HIV therapeutic approach
based on Nef7/TK VLPs expressing X4 or R5 HIV cell receptor complexes has been attempted. We here report that (CD4-CXCR4) and (CD4-
CCR5) Nef7-based VLPs efficiently enter cells infected by X4- or R5-tropic HIV-1 strains, respectively. Importantly, the delivery of the VLP-
associated Nef7/TK led to cell death upon GCV treatment. Of interest, VLPs were effective also against non-replicating, HIV-1-infected primary
human monocyte-derived macrophages. HIV-targeted VLPs represent a promising candidate for the treatment of persistently HIV-1-infected cells
that are part of virus reservoirs resistant to HAART therapies.
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The HIV-1 Nef regulatory protein is a 27-kDa product
involved in both viral infectivity and pathogenesis development
(for reviews, see Arold and Baur, 2001; Geyer et al., 2001). Its
N-terminal myristoylation ensures its localization at the cell
membrane and virion incorporation (Pandori et al., 1996;Welker
et al., 1996; Bukovsky et al., 1997), whose biological
significance is still matter of investigation, even if a role in
HIV penetration through the cortical actin network has been
recently proposed (Campbell et al., 2004). Nef disposes at cell
membrane domains enriched in cholesterol and sphingolipids
defined ‘‘detergent resistant microdomains’’ or ‘‘lipid rafts’’
(Wang et al., 2000), from which HIV preferentially buds (Manes
et al., 2000). In this regard, we previously isolated the Nef7
mutant showing an improved localization at the cell membrane
rafts correlating with a uniquely high efficiency of virion
incorporation (Peretti et al., 2005). Of note, Nef7 is defective0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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down-regulation, PAK-2 activation, and binding to the V1H
regulatory subunit of the vacuolar ATPase (D’Aloja et al., 2001).
We already described the induction of cell death upon the
challenge with VLPs incorporating the product of fusion
between Nef7 and the Thymidine Kinase from the herpes
simplex virus-1 (HSV/TK) (Peretti et al., 2005). This enzyme
phosphorylates nucleoside analogues such as ganciclovir
(GCV) or acyclovir (Moolten, 1986) that thereafter is
converted into the triphosphate counterpart by cellular kinases.
Thereby, they are incorporated in both nuclear and mitochon-
drial DNA, acting either as chain terminator or leading to the
generation of double-strand DNA breaks, leading in both cases
to cell death by apoptosis (Rubsam et al., 1998; Wei et al.,
1998; Thust et al., 2000a, 2000b).
HIV enters cells expressing the specific receptors and co-
receptors (typically CD4 and CXCR4 or CCR5), thereby
establishing a type of virus/host interaction that depends on
both the cell type and the cell activation state (for a review, see
Stevenson, 2003). In particular, HIV can either lead to cell death,
mostly in activated CD4 lymphocytes, or establishes a persistent
infection in cells controlling the extent of HIV expression and
resisting its cytopathic effect, as occurs in macrophages and6) 115 – 126
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the case the viral genome remains silent upon integration in the
host DNA. Latently infected cells could be induced to express
HIV by the treatment with either cytokines such as IL-2, anti-
CD3, gIFN, or TNFa (for a review, see Kulkosky and
Pomerantz, 2002), or with drugs like prostratin (Gulakowski
et al., 1997; Kulkosky et al., 2001; Korin et al., 2002) or 12-
deoxyphorbol-13 acetate (Bocklandt et al., 2003), leading to cell
activation in the absence of cell replication. In these cases, HIV
Env molecules undergo cell membrane exposition, thus render-
ing the infected cells readily and specifically recognizable by
viral particles carrying the respective cell receptor complex.
We sought to recover VLPs incorporating CD4 and CXCR4
or CCR5 in their envelope for the delivery of the Nef7/TK
fusion protein in HIV-infected cells. This was expected to
occur by means of the ‘‘inverse fusion’’ process, mimicking the
fusion events naturally occurring between HIV and target cells,
however, in a swapped virus to cell receptor configuration. Of
note, such a strategy has been already successfully pursued in
targeting both HIV- and SIV-infected cells with retroviral
vectors (Endres et al., 1997), in recovering pseudotyped
rhabdoviruses selectively entering HIV-1-infected cells
(Mebatsion et al., 1997; Schnell et al., 1997), and in
experiments of intervirion fusion (Zhou and Aiken, 2001).
Wehere provide evidences that Nef7-basedVLPs carrying the
viral cell receptor complexes enter HIV-1-infected cells, thereby
in the case of Nef7/TK VLPs, inducing cell killing in both
replicating and resting HIV-1-infected cells cultured with GCV.Fig. 1. Molecular analysis of Nef7-based VLPs. Western blot analysis of different
construct pCMVDR8.74 together with vectors expressing either CD4T, CXCR4,
supernatants were harvested, clarified, and concentrated. After a purification cycle
analyzed by Western blot for the presence of both Nef- and HIV-1-related products
HIV-1-related products), 1:100 (for CD4), and 1:50 (for both CXCR4 and CCR5) d
Control supernatants from mock-transfected cells processed as for the VLP recov
indicated on the left side, whereas the molecular marker sizes are reported on the rThese results allow to propose both (CD4-CXCR4) and (CD4-
CCR5) Nef7/TKVLPs as new potential therapeutic tools against
HIV-infected cells, particularly those with longer half-life.
Results
Recovery and characterization of (CD4-CXCR4) and
(CD4-CCR5) Nef7/GFP and Nef7/TK VLPs
We have already shown that the VLP-mediated intracellular
delivery of Nef7/TK led to cell death in the presence of GCV
(Peretti et al., 2005). We attempted to exploit such a
phenomenon for a new anti-HIV therapeutic strategy by
creating VLPs specifically directed to HIV-infected cells. This
was carried out by inserting HIV cell receptors, that is, CD4 and
CXCR4 or CCR5, in VLPs that, in this manner, would enter
HIV Env expressing cells through the inverse fusion process. To
this end, both CD4-CXCR4 and CD4-CCR5 pseudotyped HIV-
1-based VLPs were recovered from the supernatants of 293T
cells transiently transfected with the respective expression
vectors as detailed in the Materials and methods section. In
order to evaluate the internalization efficiency of VLPs by the
cells, Nef7/GFP incorporating VLPs were also produced.
In a first instance, the VLPs were molecularly characterized
by Western blot analyses performed on 50 ng of VLPs purified
on 20% sucrose cushion. We proved that VLPs indeed
incorporated amounts of Nef7-based fusion products compa-
rable to Nef7 alone (Figs. 1A–B) as well as the expected cellNef7-based VLPs. 293T cells were co-transfected with the HIV-1 packaging
or CCR5, and either Nef7, Nef7/TK, or Nef7/GFP. Forty-eight hours later,
on 20% sucrose cushion, 20 ng of VLPs was loaded in 10% SDS–PAGE and
(A, B), CD4 (C), CXCR4 (D), and CCR5 (E) using 1:1000 (for both Nef and
ilutions of the Abs preparations indicated in the Materials and methods section.
ery were included in all panels. The migration of relevant VLP products are
ight.
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ng/ml in supernatants, and 500–1500 ng/ml after 500
concentration.
Thus, the transient transfection on 293T cells appeared a
suitable method for producing the amounts of both (CD4-
CXCR4) and (CD4-CCR5) Nef7-based VLPs required for both
molecular and biological characterizations.
Both (CD4-CXCR4) and (CD4-CCR5) Nef7/GFP VLPs are
efficiently internalized in cells expressing X4- or R5-tropic
HIV-1
We next sought to establish whether both CD4-CXCR4 and
CD4-CCR5 pseudotyped VLPs were able to enter HIV-infected
cells. To this end, 105 X4-HIV-1 chronically infected 8E5
human T cells (whose Env expression was preventively
monitored by FACs; Fig. 2A) were infected with 50 ng of
(CD4-CXCR4) or, as control, (CD4) Nef7/GFP VLPs. Of note,
the use of higher VLP amounts was hampered by the relatively
low titers of Nef7/GFP-based VLPs we recovered (i.e., 500 ng/
ml at best). Cells were then sampled at 3, 6, and 10 h post-
infection, treated with trypsin to eliminate VLPs still bound to
the cell membrane, and analyzed by FACs. Clearly, a GFP-
fluorescent cell subpopulation was detectable in cells chal-
lenged with (CD4-CXCR4) VLPs, but not with (CD4) VLPs
(Fig. 2A). The percentages of fluorescent cells reproducibly
decreased over time likely as the consequence of the
intracellular degradation of Nef7/GFP protein. Of note, reduced
VLP inputs well correlated with decreased percentages of GFP
fluorescent cells (not shown). Similar results were obtained
using H9/HTLVIII cells (not shown).
The assay on (CD4-CCR5) Nef7/GFP VLPs was carried out
on 293T cells transfected with the R5-tropic ADA HIV-1
molecular clone. The levels of Env expression were monitored
48 h thereafter (Fig. 2B) to prove that the large majority of cells
expressed the HIV-1 receptor. Thereby, the cells were
challenged with (CD4-CCR5) Nef7-GFP VLPs or, as control,
with the counterpart carrying the CD4 receptor alone. Similarly
to that observed for the X4-tropic-infected cells, GFP-
fluorescent cells were detected within ADA HIV-1 expressing
cells challenged with (CD4-CCR5) but not with (CD4) Nef7/
GFP VLPs (Fig. 2B), thus indicating that (CD4-CCR5) VLPs
specifically entered R5-tropic Env expressing cells. Of note,
differently to that observed in (CD4-CXCR4) VLP-treated 8E5
cells, the percentage of fluorescent cells decreased to control
levels 10 h post-infection, probably the consequence of
differences in the efficiency of the intracellular protein
degradation. Also in this case, the reduction of VLP inputs
correlated with decreased percentages of GFP fluorescent cells
(not shown).
Next, we were interested in determining the correlation
between the VLP internalization efficiency and the levels of
Env products on the membrane of the target cells. To this end,
CEMss cells were infected with (VSV-G) HIV-1 and, 48 h later,
treated with 50 ng of (CD4-CXCR4) Nef7/GFP VLPs/105
cells. After 3 h, cells were analyzed by FACs for both the
gp120 Env membrane expression and VLP internalization. Asshown in Fig. 3, more than 33% of infected cells appeared
fluorescent, and higher levels of GFP-related fluorescence were
detectable in the cells most efficiently expressing the Env
product. This strongly suggests that high Env membrane
expression favors the VLP internalization that however seems
occurring also in the presence of low Env expression.
Finally, we investigated the co-receptor specificity of the
VLP entry by treating 8E5 cells with (CD4-CCR5) Nef7-GFP
VLPs or, conversely, 293T cells transfected 2 days before with
the ADA HIV-1 molecular clone with (CD4-CXCR4) Nef7-
GFP VLPs. The fact that no increases in the percentages of
fluorescent cells over the controls were detected in both
experimental conditions (not shown) enforces the idea that
the Nef7-GFP VLP entry in X4 or R5 HIV-1 expressing cells
was specifically mediated by the respective VLP co-receptor.
In conclusion, the ‘‘inverse fusion’’ process seemed nicely
operative in HIV-1-infected cells challenged with either (CD4-
CXCR4) or (CD4-CCR5) VLPs. This prompted us to
investigate the biological consequences of the challenge of
HIV-1-infected cells with Nef7/TK-based VLPs.
HIV-1 chronically infected cells are efficiently killed by
(CD4-CXCR4) Nef7/TK VLPs
To gain the proof-of-principle that (CD4-CXCR4) Nef/TK
VLPs can specifically kill HIV expressing cells, the effects on
two cell lines chronically infected by X4-tropic HIV-1 variants,
i.e., 8E5 and H9/HTLV-III, were analyzed. 105 cells were
challenged with 50 ng of (CD4-CXCR4) Nef7/TK VLPs for
three cycles, and cultured with or without GCV. As control,
cells were challenged also with the VSV-G pseudotyped Nef7/
TK VLPs. The cell cultures were monitored 7 days post-VLP
challenge, i.e., the time required for the killing of the majority
of the cells challenged with (VSV-G) Nef7/TK VLPs (not
shown). We observed that more than 90% of both (CD4-
CXCR4) VLP-challenged cells were killed when re-cultured
with GCV (Fig. 4), a result very close to that observed using
(VSV-G) VLPs. Importantly, no effects were detected in cells
challenged with VLPs and cultivated in the absence of GCV, as
well as in GCV-treated cells challenged with VLPs carrying
either VSV-G or CD4-CXCR4 receptors, but incorporating
Nef7 alone (not shown). Similarly, the challenge with (CD4-
CXCR4) VLPs had no effects in GCV-treated HIV-1-negative
cells (data not shown).
In sum, these results support the notion that the inclusion of
CD4 and CXCR4 receptors in Nef7/TK VLPs is a suitable
strategy for killing X4-tropic HIV-1-infected cells.
HIV-1 acutely infected human T lymphocytes are targeted by
(CD4-CXCR4) Nef7/TK VLPs
We next investigated the ability of (CD4-CXCR4) VLPs in
targeting HIV-1 acutely infected cells. To this end, CEM-GFP,
i.e., a human T lymphoblastoid cell line expressing the GFP
exclusively in the presence of Tat, were infected with
increasing amounts (i.e., from 2 to 50 ng) of the X4-tropic
NL4-3 HIV-1 strain. Two days thereafter, i.e., the time required
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(not shown), the cells were challenged twice with 30 ng/105
cells of (CD4-CXCR4) VLPs. Thereafter, cells were cultivated
in the presence or in the absence of GCV, and after additional 5
days, scored by FACs for the percentages of fluorescent (i.e.,
HIV-1 infected) cells. In this way, the anti-HIV effect of Nef7/
TK VLPs can be evaluated in terms of the reduction of the
percentages of fluorescent cells. Fig. 5 shows that the challenge
with (CD4-CXCR4) VLPs together with the cultivation with
GCV led to the disappearance of infected cells up to the input
of 5 ng of HIV-1/105 cells corresponding to a multiplicity of
infection (MOI) of 0.1. Consistently, by increasing the viral
input, the percentages of HIV-1-infected cells appeared
constantly reduced in VLP-treated cells compared with control
conditions. The increase of GFP-positive cells as a function of
the HIV-1 input detectable also in VLP-treated cells was likely
due to the overcoming of the number of HIV-1-infected cells
with respect to those targeted by VLPs. Of note, VLP-
unchallenged HIV-1-infected cells cultured with or withoutGCV, supported the HIV-1 replication as well as the VLP-
challenged cells re-cultured in the absence of GCV (not
shown).
These results indicate that also cells acutely infected with
X4-tropic HIV-1 can be efficiently targeted by (CD4-CXCR4)
VLPs.
HIV-1 spread is inhibited in human primary monocyte/
macrophages treated with (CD4-CCR5) Nef7/TK VLPs
Besides activated T lymphocytes, monocyte/macrophages,
dendritic cells and resting T cells are natural host cells for HIV.
These are non-replicating cells where the virus establishes a
persistent infection leading to the in vivo formation of
privileged sites where the virus efficiently resists the HAART
therapies. Being the presence of such ‘‘sanctuaries’’ sites a
major bottleneck towards HIV eradication, finding new anti-
HIV therapeutic approaches efficiently targeting non-replicat-
ing, infected cells appears a goal of a major importance. In this
Fig. 2. Nef7-GFP is efficiently delivered into the cells by both (CD4-CXCR4) and (CD4-CCR5) VLPs. Analysis of the internalization of Nef7/GFP molecules upon
the challenge of either 8E5 cells with (CD4-CXCR4) VLPs (A), or ADA HIV-1-transfected 293T cells with (CD4-CCR5) VLPs (B). Both cell cultures were
preliminarily analyzed by FACs for the membrane expression of HIV-1 gp120 using a 1:100 dilution of the 4G10 anti-gp120 mAb or the same amounts of isotype-
matched, specie-specific IgG as control. Fifty nanograms of Nef7/GFP (CD4-CXCR4) or (CD4-CCR5) VLPs were used to infect 105 of either 8E5 cells or 293T cells
48 h after the transfection with ADA HIV-1 molecular clone, respectively. As control, the same amounts of Nef7/GFP VLPs expressing CD4 alone were used. After
extensive washings, cells were incubated at 37 -C in complete medium and, after 3, 6, and 10 h, harvested, incubated 5 min with trypsin, and analyzed by FACs for
the GFP-related fluorescence. The percentages of Env or GFP-positive cells are indicated in the respective quadrants. The results are representative of three (A) and
two (B) independent experiments.
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in inhibiting the viral spread in a rather relevant cell system,
i.e., the HIV-1-infected human primary monocyte-derived
macrophages (MDM). We preventively assayed the possible
internalization of (CD4-CCR5) pseudotyped VLPs in unin-
fected MDM. To this end, we challenged MDM with (CD4-
CCR5) Nef7/GFP VLPs or, as control, Nef7/TK VLPs
deprived of receptors (‘‘null’’ VLPs). Three hours after the
absorption, the cell-associated GFP-related fluorescence was
assessed by FACs. No fluorescent cells were detected among
the MDM populations analyzed (Fig. 6A), indicating that the
CD4-CCR5 VLP pseudotyping did not per se lead to cell
internalization.Next, we evaluated the effects of (CD4-CCR5) Nef7/TK
VLPs on HIV-1-infected MDM. MDM were infected with
100 pg/105 cells of the ADA R5-tropic HIV-1 strain. Two
days thereafter, cells were challenged twice with 30 ng of
(CD4-CCR5) Nef7/TK VLPs, and cultivated in the
presence of GCV. Supernatants were harvested from 7
days post-HIV infection and the capsid (CA) p24 levels
herein measured. As shown in Fig. 6B, the challenge with
CD4-CCR5 VLPs efficiently prevented the viral spread
within the MDM cultures cultivated with GCV. The FACs
analysis carried out by labeling infected cultures with anti-
CAp24 mAb at day 11 post-infection, showed that the
decrease of HIV-1 release in the supernatants correlated
Fig. 3. The efficiency of VLP internalization in HIV-1-infected cells correlates with the levels of gp120 Env membrane expression. Analysis of the internalization of
Nef7/GFP molecules upon the challenge with (CD4-CXCR4) Nef7/GFP VLPs of CEMss cells infected 2 days before with 5 ng of (VSV-G) HIV-1/105 cells. Cells
were harvested 3 h after the VLP challenge, treated with trypsin, labeled with a 1:100 dilution of the 4G10 anti-gp120 mAb, and finally analyzed by FACs. The
percentages of gp120 Env positive, gp120 Env/GFP doubly positive, and GFP positive over the total of Env positive cells (in parentheses), are indicated in the
respective quadrants. The results are representative of two independent experiments.
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By increasing the HIV-1 input 5-folds, we observed that
VLPs still had an antiviral effect, even if with a reduced
potency likely due to the overwhelming amounts of infecting
HIV-1 (not shown). VLP-untreated MDM re-cultured with or
without GCV replicated HIV-1 as efficiently as the (CD4-
CCR5) VLP-treated MDM re-cultured without GCV did
(data not shown).Fig. 4. T-tropic HIV-1 chronically infected cells are killed upon (CD4-CXCR4)
Nef7/TK VLP challenge and GCV treatment. Cell viability expressed as
percentages of untreated cells, measured in 8E5 cells 7 days after the challenge
with Nef/TK VLPs pseudotyped by VSV-G or CD4-CXCR4 receptors, and
treated or not with GCV. 105 cells were treated with 50 ng of VLPs for three
cycles and thereafter seeded in complete medium in the presence or not of 10
AM GCV. After 7 days, the cell viability was scored by the trypan bleu
exclusion dye. As control, mock-infected 8E5 cells cultivated in the presence of
GCV were included (Ctrl). The means values TSD from seven independent
experiments are reported.Typically, only a minority of in vitro infected MDM sustains
active HIV replication, even using high MOIs. In order to
enforce our previous observations, we circumvented such a
technical limitation by reproducing the HIV-1 infection/VLP
challenging protocol using VSV-G pseudotyped HIV-1. In this
way, we already shown that the large majority of MDM
becomes infected and expresses HIV-1 proteins within 24
h (Olivetta et al., 2000). Consistently with the previous
approach, we observed that the challenging with (CD4-
CCR5) Nef7/TK VLPs of HIV-1-infected MDM coupled with
the cultivation with GCV strongly reduced the number of
infected cells (Fig. 7), thus enforcing the idea that (CD4-
CCR5) VLPs specifically target and kill HIV-1 R5-Env-
expressing cells.
In sum, (CD4-CCR5)Nef7/TK VLPs appeared effective in
clearing HIV-1-infected MDM. Hence, such VLPs may be
considered a new potential therapeutic tool for combating
persistent HIV infections in view of more effective strategies of
HIV eradication.
Discussion
We previously documented the killing activity of lentivirus-
based VLPs as the consequence of the delivery into the cells of
Nef7/TK fusion product (Peretti et al., 2005). In this paper, we
describe the generation of Nef7/TK VLPs selectively targeting
and killing HIV-1-infected cells cultivated in the presence of
GCV. This was accomplished by loading HIV cell receptor
complexes in VLPs, thus allowing their entry through the
‘‘inverse fusion’’ process. The detection of fluorescent cells in
internalization experiments we set up strongly suggested that
such a process indeed took place. In this regard, the levels of
the internalization of the (CD4-CXCR4) Nef7-GFP VLPs
apparently correlated with the Env gp120 expression extents on
Fig. 5. Selective elimination of human T cells acutely infected with X4-tropic HIV-1 upon challenging with (CD4-CXCR4) Nef7/TK VLPs. Percentages of
fluorescent cells scored by FACs analysis of CEM-GFP cells infected with increasing doses of T-tropic HIV-1 and challenged with (CD4-CXCR4) Nef7/TK VLPs.
As summarized in the scheme reported on the left, CEM-GFP cells were infected with 2–50 ng of NL4-3 HIV-1/105 cells by adsorbing the viral inoculum in 50 Al for
2 h at 37 -C. Thereafter, cells were kept in culture for 2 days, and then challenged with 30 ng of VLPs/105 cells for two cycles. Finally, cells were re-fed in complete
medium in the presence or in the absence of GCV, and monitored for the GFP-associated fluorescence after additional 5 days. Results are the means values from two
independent experiments.
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contribute to the overall efficiency of the intracellular delivery
of Nef7-derived products, such as the intracellular degradation
activities, and the levels of incorporation of Nef7-based
products in truly infective VLPs. Anyway, the specificity of
the results we obtained from the internalization assays was
ensured by two order of controls: (i) the trypsin treatment, that
removed the extra-cellular fluorescence from still membrane-
bound viral particles, and (ii) the use of CD4 expressing Nef7/
GFP VLPs, accounting for the possible internalization of VLPs
by endocytosis (i.e., through a receptor-independent mecha-
nism) (Fackler and Peterlin, 2000; Schaeffer et al., 2001), that
was reported to be favored by the presence of CD4, at least in T
cells (Schaeffer et al., 2004).
We here provide evidences that both 8E5 and H9/HTLV-III
cells were susceptible to the combined effect of (CD4-CXCR4)
VLPs and GCV. In terms of percent of surviving cells, this effect
seemed slightly but reproducibly less efficient compared with
that detectable upon the challenge with equal amounts of the
VSV-G pseudotyped VLP counterpart. This likely correlated
with the already well-described lower efficiency of the pH-
independent virus-to-cell fusion driven by CD4 and co-
receptors compared with the pH-dependent viral entry induced
by the VSV-G (Aiken, 1997). Non-optimal levels of internal-
ized HSV-TK could also associate with suboptimal cellular
kinase activity for the conversion of monophosphate GCV into
the concentration of the triphosphate counterpart required for
the induction of the apoptotic effect.
We demonstrated that the challenge with (CD4-CXCR4)
Nef7/TK VLPs almost completely eliminated CEM-GFP cellsinfected with X4-HIV-1 amounts corresponding to up to 0.1
MOI, meanwhile resulting in impaired percentages of HIV-1-
infected cells upon infection with higher MOIs. Such an
inhibitory effect could appear in a first instance surprising, as
the lag we measured for the VLP/GCV-induced cell death in
HIV-1 chronically infected cells ranged from 4 to 6 days, thus
basically exceeding the expected life span of HIV-1-infected
CEM-GFP cells (3–4 days, as we evaluated by single-cycle
infection with VSV-G pseudotyped Denv HIV-1, not shown).
This, however, may be explained by admitting that the TK/
GCV cytotoxicity acts synergistically with the anti-cellular
effects of HIV-1, thus resulting in a strongly accelerated death
of acutely infected cells and, by consequence, in an overall
impairment of HIV spread.
We feel the results we obtained in HIV-1-infected MDM
cultures would have a therapeutic relevance due that macro-
phages strongly contribute to the HIV persistency, even during
the HAART treatment. Of note, the VLP-induced killing of
HIV-1-infected cells that, like MDM, do not duplicate should
not be considered unexpected as it reproduces data we already
described in uninfected MDM challenged with (VSV-G) Nef7/
TK VLPs (Peretti et al., 2005).
In sum, the here reported results appear to be promising in
the perspective of developing new Nef7/TK VLP-based
therapeutic strategies mainly targeted to persistently HIV-
infected cells such as monocyte/macrophages, dendritic cells,
and resting T lymphocytes. In addition, the treatment with
Nef7/TK VLPs could have some impact also against latently
infected T lymphocytes in the case the HIV expression is
pharmacologically induced.
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overall therapeutic outcome from the VLP challenge could be
still ameliorated by recovering ‘‘second generation’’ VLPsincluding already described HSV/TK-derived enzymes with
stronger activity (Loubiere et al., 1999; Qiao et al., 2000), and/
or using nucleosides analogues with shorter time of action
Fig. 7. Selective elimination of HIV-1 expressing MDM upon challenge with (CD4-CCR5) Nef7/TK VLPs. Five days old MDM were infected with 1 ng of (VSV-G)
HIV-1/105 cells or left untreated (Ctrl). After 24 h, infected MDM were challenged or not with 50 ng/105 cells of (CD4-CCR5) Nef7/TK VLPs for three cycles, and
cultivated in the presence or absence of GCV. After additional 4 days, the percentages of HIV-1 Gag expressing cells were evaluated by FACs analyses. Percentages
of positive cells are reported in the respective panels. Data are representative of the analysis performed on MDM from two healthy donors.
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CXCR4 and CCR5 co-receptors may restrict the VLP
infectivity in vivo, it will be of utility the recovery of Nef7/
TK-based VLPs incorporating a VSV-G deletion mutant (‘‘G
stem’’) that was demonstrated to relieve the CXCR4 or CCR5Fig. 6. Blocking of viral spread upon challenge with (CD4-CCR5) Nef7/TK V
internalization of Nef7/GFP molecules upon the challenge of MDM with either (CD4
‘‘null’’ VLPs). Cells were harvested 3 h after the VLP challenge, treated with tryps
MDM. (B) HIV-1 amounts measured as ng/ml of CAp24 in supernatants harvested a
HIV-1 followed, 2 days after, by two cycles of challenge with 30 ng/105 cells of
representative of independent experiments performed on MDM from three healthy
products in MDM 11 days after the infection with ADA HIV-1, followed by VLP
intensity detected in uninfected MDM labeled with the anti-Gag mAb. Percentagesrequirement for CD4-dependent HIV-1 Env-mediated fusion
(Jeetendra et al., 2002). By consequence, and interestingly
enough, G stem incorporating VLPs is expected to be equally
effective against cells infected by either X4- or R5-tropic HIV
isolates.LPs of MDM acutely infected with R5-tropic HIV-1. (A) Analysis of the
-CCR5) Nef7/GFP VLPs or, as controls, with the receptor-less counterpart (i.e.,
in, and analyzed by FACs for the GFP-related fluorescence. Ctrl: unchallenged
t the indicated days after the infection of MDM with 100 pg/105 cells of ADA
(CD4-CCR5) Nef7/TK VLPs, and cultivation with or without GCV. Data are
donors. (C) FACs analysis for the cytoplasmic accumulation of CAp24-related
challenge and cultivation with or without GCV. Bars limit the fluorescence
of positive cells are reported in the respective panels.
S. Peretti et al. / Virology 345 (2006) 115–126124Furthermore, as we already observed that Nef7 is
incorporated at high levels also in both simian immunodefi-
ciency virus (not shown) and Moloney leukemia virus viral
particles (Peretti et al., 2005), the respective VLPs could be
usefully employed also for both experimental and pre-clinical
tests of new peptidic drugs in primates as well as in rodents.
In this respect, the possibility to incorporate high levels of
Nef7-derived products in virions of different virus species
would offer the possibility to select the type of VLPs showing
the best stability in vivo. Finally, together with the already
described Vpr-GFP (McDonald et al., 2002), Nef7/GFP
would be part of a new generation of fluorescent HIV-1




293T cells were grown in Dulbecco’s modified Eagle’s
medium supplemented with 10% decomplemented Fetal Calf
Serum (dFCS). CEMss and CEM-GFP (Gervaix et al., 1997)
were cultivated in RPMI 1640 (Life Technologies, Milan, Italy)
supplemented with 10% dFCS. The same medium was used for
H9/HTLVIII (Popovic et al., 1984) and 8E5 cells (Folks et al.,
1986), i.e., human T lymphoblastoid cell lines expressing a
nef-deleted infectious HIV-1, and an RT-defective, non-
infectious HIV-1, respectively. PBMC were isolated from the
buffy coat obtained from 20 to 40 years old healthy male
donors. Monocytes were isolated by 1 h adherence of PBMC
followed by a immune-magnetic depletion of non-monocytic
cells carried out by means of a selection kit from Miltenyi
(Auburn, CA) used following the manufacturer’s recommenda-
tions. The purity of recovered cell populations was assayed by
FACS analysis by means of phycoerythrin (PE)-conjugated
anti-CD14 mAb (Becton Dickinson, Mountain View, CA)
labeling. Cell preparations staining below 95% positive for
CD14 (a cell surface marker specific for monocyte-macrophage
cell populations) were discarded. Monocytes were cultured in
48-well plates in RPMI 1640 supplemented with 20% dFCS for
5–7 days before challenges. Ganciclovir was from Synthex
Laboratories, Inc., Palo Alto, CA, and was used at the
concentration of 10–30 AM.
VLP and HIV-1 production, infection, and detection
Preparations of VLPs pseudotyped with the CD4 and
CXCR4 or CCR5 HIV cell receptors were obtained from the
supernatants of 293T cells 48–60 h after the calcium phosphate
co-transfection of molar equivalent amounts of the
pCMVDR8.74 packaging vector (Dull et al., 1998), and
vectors expressing, respectively, Nef7, Nef7/GFP (D’Aloja et
al., 2001), or Nef7/TK, the human CD4 receptor truncated in
its intracytoplasmic domain (Aiken et al., 1994), and either
human CXCR4 (Baiocchi et al., 1997) or CCR5 (by pc.CCR5,
contributed by Nathaniel Landau). Supernatants were clarified
and concentrated by ultracentrifugation on SW 41 rotor,45,000  g, 1.30 h at 4 -C. In some instances, the concentrated
VLPs were purified through additional ultracentrifugation (SW
60 rotor, 65,000  g, 4 h at 4 -C) on 20% sucrose cushions.
VLP preparations were titrated both by measuring HIV-1
CA p24 contents by quantitative ELISA (Abbott, Abbott Park,
Illinois) and by the reverse transcriptase assay (Rossi et al.,
1987). Challenges were performed by spinoculation, i.e., the
adsorption of VLPs to cells by means of 1 h of centrifugation at
150  g at r.t. Afterwards, the cells were re-fed by adding fresh
medium complemented or not with GCV. In Nef7-GFP VLP
internalization experiments, cells were washed to eliminate
non-adsorbed virions and seeded in complete medium. At
different intervals, cells were harvested, treated with trypsin for
5 min at r.t., and finally analyzed by FACs. In general, the VLP
input and the number of challenge cycles depended on the
expected number of target cells as well as on the titers of VLP
preparations, except than in the internalization experiments,
where the kinetic studies required a single VLP challenge.
The evaluation of cell mortality was performed by both the
trypan blue exclusion dye, and scoring the percentages of
labeled cells by FACs after treatment with 5 Ag/ml of
propidium iodide (PI).
Infectious HIV-1 viral preparations were obtained from the
supernatants of 293T cells 48 h after the transfection with
vectors expressing the X4-tropic NL4-3 (Adachi et al., 1986) or
the R5-tropic ADA (Theodore et al., 1996) HIV-1 genomes.
Supernatants were clarified and concentrated by ultracentrifu-
gation as described (D’Aloja et al., 2001). HIV-1 titrations
were performed as for VLP preparations. For the recovery of
pseudotyped HIV-1, 293T cells were co-transfected with the
pNL4-3 molecular clone and a VSV-G expressing vector in a
5:1 molar ratio. Supernatants were harvested 48 h thereafter,
clarified and concentrated by ultracentrifugation.
Western blot analysis
Both cells and purified VLP preparations were lysed in
PBS, 1% Triton-X100 in the presence of anti-proteolytic
agents. For the preparation of cytoplasmic extracts, whole cell
lysates were centrifuged at 6,000  g for 10 min at 4 -C, and
the supernatants frozen at 80 -C. Aliquots of 30 Ag of total
cell proteins were run in 10% SDS–PAGE, thereby undergoing
to immunoblotting analysis. The following mono- or polyclon-
al Abs served for the revelation of VLP associated products: a
pool of strongly reactive HIV-1-positive sera, ARP 444 sheep
anti-Nef antiserum (generously provided by Mark Harris,
University of Leeds, Leeds, UK), anti human CD4 mAb,
clone 1F6 (Novacastra, Newcastle, UK), anti-human CXCR4
mAb clone C-20 (Santa Cruz Biotechnology, Santa Cruz, CA),
and anti-human CCR5 mAb clone H-185 (Santa Cruz
Biotechnology).
Flow cytometry analyses
For the detection of HIV-1 Env gp120, 3  105 cells were
incubated with a 1:100 dilution of the 4G10 anti-gp120 mAb
or, as control, with a isotype-matched, specie-specific irrele-
S. Peretti et al. / Virology 345 (2006) 115–126 125vant mAb for 1 h at 4 -C. Thereafter, cells were washed and
labeled for 1 h at r.t. with a l:100 dilution of fluorescein
isothiocyanate (FITC) or phycoerythrin (PE)-conjugated goat
anti-mouse IgG. Cell populations were finally analyzed by
FACs. For the detection of HIV-1 Gag-related products, MDM
were treated with Permeafix (Ortho Diagnostic, Raritan, NJ)
for 30 min at r.t., and then labelled for 1 h at r.t. with a l:50
dilution of PE-conjugated anti-CAp24 KC-57 mAb (Coulter
Corp. Hialeah, FL).
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